Jeil Pharmaceutical Co.,Ltd (KRX: 271980)

Jeil Pharmaceutical Co.,Ltd Statistics

Total Valuation

Jeil Pharmaceutical Co.,Ltd has a market cap or net worth of KRW 187.97 billion. The enterprise value is 243.57 billion.

Market Cap	187.97B
Enterprise Value	243.57B

Important Dates

The last earnings date was Sunday, November 10, 2024.

Earnings Date	Nov 10, 2024
Ex-Dividend Date	Dec 27, 2024

Share Statistics

Jeil Pharmaceutical Co.,Ltd has 14.57 million shares outstanding. The number of shares has decreased by -0.01% in one year.

Current Share Class	n/a
Shares Outstanding	14.57M
Shares Change (YoY)	-0.01%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	13.15%
Owned by Institutions (%)	1.64%
Float	5.42M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.27
PB Ratio	1.09
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-6.82
EV / Sales	0.35
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-32.87

Financial Position

The company has a current ratio of 1.11, with a Debt / Equity ratio of 0.39.

Current Ratio	1.11
Quick Ratio	0.69
Debt / Equity	0.39
Debt / EBITDA	n/a
Debt / FCF	-9.98
Interest Coverage	-3.55

Financial Efficiency

Return on equity (ROE) is -20.79% and return on invested capital (ROIC) is -5.13%.

Return on Equity (ROE)	-20.79%
Return on Assets (ROA)	-2.70%
Return on Capital (ROIC)	-5.13%
Revenue Per Employee	724.37M
Profits Per Employee	-36.96M
Employee Count	967
Asset Turnover	1.43
Inventory Turnover	4.50

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -21.08% in the last 52 weeks. The beta is 1.12, so Jeil Pharmaceutical Co.,Ltd's price volatility has been higher than the market average.

Beta (5Y)	1.12
52-Week Price Change	-21.08%
50-Day Moving Average	14,346.80
200-Day Moving Average	15,759.75
Relative Strength Index (RSI)	29.82
Average Volume (20 Days)	10,193

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Jeil Pharmaceutical Co.,Ltd had revenue of KRW 700.47 billion and -35.74 billion in losses. Loss per share was -2,453.00.

Revenue	700.47B
Gross Profit	172.38B
Operating Income	-21.23B
Pretax Income	-37.20B
Net Income	-35.74B
EBITDA	-10.68B
EBIT	-21.23B
Loss Per Share	-2,453.00

Balance Sheet

The company has 34.31 billion in cash and 73.92 billion in debt, giving a net cash position of -39.61 billion or -2,718.36 per share.

Cash & Cash Equivalents	34.31B
Total Debt	73.92B
Net Cash	-39.61B
Net Cash Per Share	-2,718.36
Equity (Book Value)	188.95B
Book Value Per Share	11,869.41
Working Capital	32.51B

Cash Flow

In the last 12 months, operating cash flow was -2.99 billion and capital expenditures -4.42 billion, giving a free cash flow of -7.41 billion.

Operating Cash Flow	-2.99B
Capital Expenditures	-4.42B
Free Cash Flow	-7.41B
FCF Per Share	-508.55

Margins

Gross margin is 24.61%, with operating and profit margins of -3.03% and -5.10%.

Gross Margin	24.61%
Operating Margin	-3.03%
Pretax Margin	-5.31%
Profit Margin	-5.10%
EBITDA Margin	-1.52%
EBIT Margin	-3.03%
FCF Margin	-1.06%

Dividends & Yields

This stock pays an annual dividend of 50.00, which amounts to a dividend yield of 0.40%.

Dividend Per Share	50.00
Dividend Yield	0.40%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.01%
Shareholder Yield	0.41%
Earnings Yield	-19.02%
FCF Yield	-3.94%

Stock Splits

The last stock split was on April 11, 2018. It was a forward split with a ratio of 1.4.

Last Split Date	Apr 11, 2018
Split Type	Forward
Split Ratio	1.4

Scores

Jeil Pharmaceutical Co.,Ltd has an Altman Z-Score of 1.7. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.7
Piotroski F-Score	n/a